Intestinal Diseases
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
Subtype terms (25)
More specific conditions that are subtypes of Intestinal Diseases in the MeSH hierarchy.
- Cecal Diseases
- Colonic Diseases
50 drugs (30 approved, 20 experimental)
- Duodenal Diseases
1 drug experimental
- Dysentery
15 drugs (7 approved, 8 experimental)
- Enteritis
21 drugs (7 approved, 14 experimental)
- Enterocolitis
13 drugs (7 approved, 6 experimental)
- HIV Enteropathy
1 drug approved
- Ileal Diseases
- Inflammatory Bowel Diseases
223 drugs (116 approved, 107 experimental)
- Intestinal Atresia
3 drugs approved
- Intestinal Diseases, Parasitic
2 drugs approved
- Intestinal Failure
8 drugs (4 approved, 4 experimental)
- Intestinal Fistula
6 drugs (3 approved, 3 experimental)
- Intestinal Neoplasms
525 drugs (265 approved, 260 experimental)
- Intestinal Obstruction
14 drugs (13 approved, 1 experimental)
- Intestinal Perforation
6 drugs approved
- Intestinal Polyposis
9 drugs (8 approved, 1 experimental)
- Jejunal Diseases
- Malabsorption Syndromes
33 drugs (14 approved, 19 experimental)
- Mesenteric Ischemia
6 drugs (5 approved, 1 experimental)
- Mesenteric Vascular Occlusion
- Pneumatosis Cystoides Intestinalis
2 drugs experimental
- Protein-Losing Enteropathies
7 drugs (4 approved, 3 experimental)
- Rectal Diseases
23 drugs (13 approved, 10 experimental)
- Zollinger-Ellison Syndrome
15 drugs (12 approved, 3 experimental)
Drugs by status
Phase 4 trials (34)
- ringer's lactate
- albendazole
- betaine
- prednisone
- Diatrizoate
- lactulose
- simethicone
- albumin (Human)
- somatostatin
- adalimumab
- ropivacaine
- acetaminophen
- lidocaine
- prucalopride succinate
- epinephrine
- hyaluronic acid
- rocuronium
- levobupivacaine
- bupivacaine
- thiopurine
- furosemide
- ondansetron
- lactobacillus plantarum
- neostigmine
- budesonide
- amino acids
- oxygen
- morphine
- sodium chloride
- sugammadex
- +4 more
Phase 3 trials (35)
- metronidazole
- anisodamine
- alvimopan
- procaine benzylpenicillin
- bisacodyl
- clavulanate
- egg
- mesalamine
- bovine colostrum
- soybean oil
- metoclopramide
- nitazoxanide
- sodium picosulfate
- magnesium sulfate
- scopolamine
- rifaximin
- sennosides a&b
- cyclophosphamide
- sufentanil
- sulfur hexafluoride lipid-type a microspheres
- bevacizumab
- fluconazole
- tripterygium wilfordii
- nicotinamide
- infliximab
- azithromycin
- cefuroxime
- opium alkaloids
- diatrazoate meglumine
- prednisolone
- +5 more
Phase 2 trials (31)
- anlotinib
- anti-interferon-gamma monoclonal antibody
- human fibrin
- crofelemer
- da jian zhong tang
- fluorouracil
- paclitaxel
- khk4083
- leucovorin
- npo-13
- cow milk
- pectin
- lanreotide
- alectinib
- sgm-101
- sacrosidase
- alteplase
- ustekinumab
- capecitabine
- autologous microbiome
- human fecal microbiota
- menthol
- dexmedetomidine
- nexvax2
- oxaliplatin
- tranexamic acid
- cisplatin
- green banana flour
- methylnaltrexone
- monoammonium glycyrrinate
- +1 more
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (50)
- AbbVie
- Daiichi Sankyo
- Astellas
- Merck
- Pfizer
- World Health Organization
- Huazhong University of Science and Technology
- University of Pittsburgh
- Albert Schweitzer Hospital
- Boston University
- Cedars-Sinai Medical Center
- Federal University of Juiz de Fora
- McGill University
- Oregon Health and Science University
- Universidad Autonoma de Madrid
- University of Groningen
- University of Nottingham
- University of Tennessee
- University of Alberta
- Mayo Clinic
- Fudan University
- University of British Columbia
- University of Copenhagen
- University of Ulsan
- University of Amsterdam
- Free University of Amsterdam
- Jiao Tong University
- American University of Beirut
- Hebrew University
- Rush University
- +20 more
Organization Involved with Phase 3 Indications (58)
- Regeneron
- Takeda
- Bausch Health Companies
- Cubist
- GlaxoSmithKline
- Institut Pasteur
- MedVadis Research Corporation
- Ocera Therapeutics
- Parexel
- Pharmacosmos
- Shield Therapeutics
- Vifor Inc.
- Boehringer Ingelheim
- Sucampo
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Cornell University
- Institut National de la Santé Et de la Recherche Médicale, France
- Nanjing Medical University
- Nanjing University
- Osaka University
- Pierre and Marie Curie University
- Stanford University
- University of Florence
- University of Messina
- University of Oslo
- University of Pavia
- University of Pisa
- University of Rochester
- University of Toronto
- University of Vermont
- +28 more
Organization Involved with Phase 2 Indications (52)
- 4SC AG
- Facet Biotech
- Galapagos NV
- Cato Research
- Gilead Sciences
- Progenics
- Sanofi
- Shionogi
- Ipsen
- Novartis
- Arena Pharmaceuticals
- Catalysis SL
- ImmusanT, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Kyowa Hakko Kirin
- Nihon Pharmaceutical Co., Ltd
- Imagine Institute
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Region Syddanmark
- Third Military Medical University
- Arizona State University
- Brown University
- Harvard University
- Emory University
- Harokopio University
- Indiana University
- Katholieke Universiteit Leuven
- Northwell Health
- Santa Barbara Cottage Hospital
- +22 more
Organization Involved with Phase 1 Indications (23)
- Eisai
- Theravance
- Celgene
- Blueprint Medicines Corporation
- Cantex Pharmaceuticals
- Seattle Children's Hospital
- University of Washington
- International Vaccine Institute
- McMaster University
- Michigan State University
- University of Zurich
- Xiamen University
- University of California, San Francisco
- University of Colorado, Denver
- The Spectrum Health Group
- Mitsubishi Tanabe
- University of Montreal
- University of Texas at Houston
- National Institute of Cholera and Enteric Diseases, Kolkata, India
- Children's National Medical Center
- University of Colorado
- Chinese Academy of Medical Sciences
- Children's Hospital Los Angeles
Organization Involved with Other Experimental Indications (40)
- AstraZeneca
- Centocor
- Beneo GmbH
- Danisco
- Lesaffre International
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Center for Research Resources (NCRR)
- Uniformed Services University of the Health Sciences
- United States Department of Agriculture
- United States Navy
- University of Pennsylvania
- Maastricht University
- University of Manitoba
- Bay Area Retina Associates
- Baylor University
- Case Western Reserve University
- University of London
- Hillel Yaffe Medical Center
- Medical University of Gdansk
- Medical University of Warsaw
- Radboud University
- Silesian University of Medicine
- Texas A&M University
- University of Ottawa
- Utrecht University
- Wroclaw Medical University
- Zagazig University
- Poznan University
- University of Calgary
- University of Chicago
- +10 more